Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Eye Tech Care's Ultrasound Glaucoma Treatment Approved for China Use

publication date: Nov 1, 2017

Eye Tech Care SA, a French medical device company, received CFDA approval to begin marketing its EyeOP1® glaucoma treatment product in China. EyeOP1 is an high-intensity focused ultrasound device that is the first non-invasive treatment for glaucoma in China. It treats the disease in a three-minute session that has little risk of side effects. In early 2016, Eye Care Tech raised $27 million in funding from China's Everpine Capital to support China development of the device. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
September 20-21 | Shanghai
September 25-26 | Digital
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China